Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

August 10, 2018: By Joan McKenna

Glaukos announced Aug. 2 that it would collaborate with D. Western Therapeutics Institute (DWTI) of Japan on development of glaucoma drugs using compounds from DWTI’s proprietary ROCK inhibitor compound library. Glaukos is known for developing the first minimally invasive glaucoma surgical device, the iStent, launched in 2012.

Glaukos CEO Thomas Burns said compounds resulting from the partnership potentially could be delivered using Glaukos’ clinical-stage iDose drug delivery system.

Glaukos will pay DWTI an upfront technology access fee and research support fees.

The San Clemente, California, will evaluate the compounds and has the exclusive right to develop any resulting intracameral or topical products.

Glaukos also reported Q2-2018 net sales of $43.2 million, a 5 percent increase over Q2-2017. It raised its 2018 net sales guidance to $162 million to $166 million from $160 million to $165 million.

Glaukos said it plans to accelerate its pivotal Phase III trial of iDose Travoprost to target FDA approval in 2021 or 2022, a year earlier than planned. The randomized trial is currently recruiting patients, with target enrollment of a thousand subjects.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT